Press Releases

Date Title and Summary Additional Formats
Toggle Summary

Fate Therapeutics Announces Day 100 Clinical Results from Phase 1 Stage of PROTECT Trial of ProTmune™ and Initiation of Phase 2 Stage

All Subjects Achieved Day 100 Relapse-free Survival All Incidents of Day 100 Acute GvHD Responded to Steroid Treatment Randomized, Controlled and Double-Blinded Phase 2 Stage of PROTECT Now Enrolling SAN DIEGO, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. Read All » 		View HTML
Toggle Summary

Fate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

SAN DIEGO, Dec. 15, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced the closing of an underwritten public offering of Read All » 		View HTML
Toggle Summary

Fate Therapeutics and University of California San Diego Launch Research Collaboration to Develop iPSC-Derived CAR NK Cell Cancer Immunotherapies

Product Candidates to Incorporate Chimeric Antigen Receptor Construct Optimized for NK Cell Persistence and Anti-Tumor Activity Master Pluripotent Cell Lines Engineered with Chimeric Antigen Receptors to be used for Off-the-Shelf Targeted Natural Killer Cell Product Candidates SAN DIEGO, Dec. Read All » 		View HTML
Toggle Summary

Fate Therapeutics and Regents of the University of Minnesota Expand Research Collaboration for Clinical Translation of Engineered iPSC-Derived Natural Killer Cell Cancer Immunotherapy

Off-the-Shelf Natural Killer Cell Therapy Being Developed to Complement Standard-of-Care Monoclonal Antibody Treatment for Cancer First-of-Kind Product Candidate to be Manufactured from an Engineered Induced Pluripotent Stem Cell Line Intellectual Property Covering Compositions of Novel CD16 and Read All » 		View HTML
Displaying 31 - 34 of 34 results

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.

MENU